Bank of New York Mellon Corp increased its position in Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) by 15.2% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 134,277 shares of the specialty pharmaceutical company’s stock after acquiring an additional 17,767 shares during the period. Bank of New York Mellon Corp owned approximately 0.89% of Eagle Pharmaceuticals worth $8,008,000 at the end of the most recent reporting period.
Other hedge funds have also recently added to or reduced their stakes in the company. Janus Henderson Group PLC acquired a new position in Eagle Pharmaceuticals during the 2nd quarter valued at about $144,384,000. Thrivent Financial For Lutherans increased its stake in Eagle Pharmaceuticals by 17,917.8% during the 2nd quarter. Thrivent Financial For Lutherans now owns 828,820 shares of the specialty pharmaceutical company’s stock valued at $65,386,000 after buying an additional 824,220 shares during the period. Old Mutual Global Investors UK Ltd. increased its stake in Eagle Pharmaceuticals by 271.6% during the 3rd quarter. Old Mutual Global Investors UK Ltd. now owns 386,132 shares of the specialty pharmaceutical company’s stock valued at $23,028,000 after buying an additional 282,225 shares during the period. Lazard Asset Management LLC grew its stake in shares of Eagle Pharmaceuticals by 1,045.7% in the 2nd quarter. Lazard Asset Management LLC now owns 278,108 shares of the specialty pharmaceutical company’s stock worth $21,939,000 after purchasing an additional 253,833 shares during the last quarter. Finally, Prudential Financial Inc. grew its stake in shares of Eagle Pharmaceuticals by 808.7% in the 3rd quarter. Prudential Financial Inc. now owns 222,072 shares of the specialty pharmaceutical company’s stock worth $13,244,000 after purchasing an additional 197,634 shares during the last quarter.
Shares of Eagle Pharmaceuticals, Inc. (EGRX) opened at $62.56 on Friday. The company has a current ratio of 5.30, a quick ratio of 5.15 and a debt-to-equity ratio of 0.26. The company has a market cap of $925.14, a P/E ratio of 10.07 and a beta of 1.24. Eagle Pharmaceuticals, Inc. has a fifty-two week low of $45.05 and a fifty-two week high of $97.15.
Several brokerages have recently issued reports on EGRX. ValuEngine raised shares of Eagle Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Monday, October 2nd. Zacks Investment Research cut shares of Eagle Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday. Mizuho reaffirmed a “sell” rating and issued a $37.00 price objective on shares of Eagle Pharmaceuticals in a research note on Wednesday, November 8th. BidaskClub upgraded shares of Eagle Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, December 2nd. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $75.00 target price (down from $81.00) on shares of Eagle Pharmaceuticals in a report on Thursday, November 9th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the stock. Eagle Pharmaceuticals has an average rating of “Hold” and an average target price of $62.33.
TRADEMARK VIOLATION NOTICE: This article was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this article on another domain, it was illegally stolen and reposted in violation of international copyright law. The original version of this article can be read at https://www.dispatchtribunal.com/2018/01/12/eagle-pharmaceuticals-inc-egrx-position-boosted-by-bank-of-new-york-mellon-corp.html.
Eagle Pharmaceuticals Profile
Eagle Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company’s product portfolio includes products, including Argatroban; Ryanodex; docetaxel injection, non-alcohol formulation; and Bendeka.
Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.